tiprankstipranks
Advertisement
Advertisement

Enlivex’s RAIN Treasury Token Debuts on Kraken to Boost Liquidity

Story Highlights
  • Enlivex’s primary treasury asset, the RAIN token, began trading on the Kraken cryptocurrency exchange on February 9, 2026.
  • The Kraken listing is expected to enhance liquidity, price discovery and investor access to RAIN, reinforcing Enlivex’s distinctive digital asset treasury strategy.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Enlivex’s RAIN Treasury Token Debuts on Kraken to Boost Liquidity

Claim 55% Off TipRanks

Enlivex ( (ENLV) ) has shared an announcement.

On February 10, 2026, Enlivex Therapeutics reported that its primary treasury asset, the RAIN token, was listed on the Kraken cryptocurrency exchange effective February 9, 2026. Kraken, one of the most established and liquid U.S.-based digital asset platforms, serves millions of users globally and handled more than $2 trillion in trading volume in 2025.

Enlivex expects that access to RAIN through Kraken will bolster secondary market liquidity, improve price discovery, and broaden participation in the RAIN ecosystem. The listing underscores the company’s distinctive strategy of integrating a decentralized governance and utility token from an Arbitrum-based predictions and options protocol into its balance sheet, potentially strengthening the visibility and market dynamics of both RAIN and Enlivex’s shares among digital asset-focused investors.

The most recent analyst rating on (ENLV) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Enlivex stock, see the ENLV Stock Forecast page.

Spark’s Take on ENLV Stock

According to Spark, TipRanks’ AI Analyst, ENLV is a Neutral.

The score is held down mainly by weak financial performance (no revenue, ongoing losses, and persistent cash burn despite improvement) and a valuation profile dominated by negative earnings. Technicals provide partial support due to a clear uptrend, but overbought momentum readings add near-term risk.

To see Spark’s full report on ENLV stock, click here.

More about Enlivex

Enlivex Therapeutics Ltd. is a clinical-stage macrophage reprogramming immunotherapy company focused on the late-stage development of Allocetra, a novel therapy aimed at treating osteoarthritis. The Israel-based, Nasdaq-listed firm is also the first public company to center its corporate treasury strategy on the RAIN token, using the digital asset as its primary treasury reserve to give investors exposure to RAIN as a form of digital capital.

Average Trading Volume: 4,102,048

Technical Sentiment Signal: Hold

Current Market Cap: $275.4M

Find detailed analytics on ENLV stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1